Drug Database
PA

pantoprazole

✓ Approved

Nanodaru · ATP4A · 小分子

什么是 pantoprazole?

pantoprazole 是一种小分子,由Nanodaru研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司Nanodaru
药物类别小分子
分子靶点ATP4A
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

pantoprazole 作用于 1 个分子靶点:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pantoprazole 针对 4 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastrinoma✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

相关研究文献

PubMedCritical care medicine2026-11-18

ICU Mortality Associated With Clinically Important Upper Gastrointestinal Bleeding: A Multistate Analysis.

Wang Yang Y, Heels-Ansdell Diane D, Parpia Sameer S, Cook Deborah D et al.

Clinically important upper gastrointestinal bleeding may increase mortality and time to discharge from the ICU. Conventional analyses ignore timing and treat bleeding as a binary event. We evaluated the association between time-dependent clinically important upper gastrointestinal bleeding and ICU mortality. A multicenter cohort study using data from an international stress ulcer prophylaxis trial. A total of 4821 invasively ventilated adult participants. None. A multistate model was specified with two transient ICU states (bleed-free and post-bleed) and four absorbing states (ICU discharge or death, each with or without bleeding). The Aalen-Johansen method was used to estimate transition and state occupancy probabilities and to describe risks of different clinical courses. Follow-up was censored at 90 days. We fit two Cox models for time to death in the ICU regressing on time-dependent bleeding history while adjusting for age, sex, baseline Acute Physiology and Chronic Health Evaluation II score, admission category (medical/surgical/trauma), vasopressor/inotrope use and renal replacement therapy on study day 1 and randomized allocation of pantoprazole or placebo; a second model also adjusted for time-dependent covariates of advanced life support (invasive mechanical ventilation, vasopressor/inotrope use, and renal replacement therapy). Clinically important upper gastrointestinal bleeding developed in 104 patients (2.2%) in the ICU. Median ICU length of stay for those who experienced bleeding was 19 days (interquartile range [IQR], 11-30 d) vs. 9 days (IQR, 5-15 d) for those who did not. Accounting for immortal time bias, the time-dependent indicator of clinically important upper gastrointestinal bleeding was associated with increased ICU mortality (hazard ratio, 1.56; 95% CI, 1.13-2.15). At any time, patients who experienced bleeding had approximately 1.6 times the hazard of ICU mortality compared with those without a history of bleeding. Clinically important upper gastrointestinal bleeding as a time-dependent event is associated with an increased risk of ICU mortality.

PMID 43049476
阅读全文 →
PubMedScientifica2026-11-16

Spectroscopic and Computational Investigation of the Interaction of Glimepiride and Pantoprazole With Bovine Serum Albumin.

Deepa Kanij Nahar KN, Nawsheen Sabia S, Sufian Md Abu MA, Hasan A H M Nazmul AHMN

This study investigated the binding interactions of glimepiride and pantoprazole with bovine serum albumin (BSA) to evaluate potential drug-drug and drug-protein interactions that may influence pharmacokinetics and pharmacodynamics. Protein binding was studied using UV spectroscopy and equilibrium dialysis. Molecular docking, molecular dynamics (MD) simulations, and principal component analysis (PCA) were performed to characterize the binding interactions and structural stability of the drug-protein complexes. Equilibrium dialysis and spectroscopic analysis revealed that both glimepiride and pantoprazole increase the percentage of the free fraction of each other. Besides, glimepiride proved to have the stronger affinity for BSA than that of pantoprazole. Both test drugs were found to interact at the warfarin-binding site (Site I) of BSA in an unbiased molecular docking study, although spectroscopic site-probe analysis showed that Site I is pantoprazole's primary binding site and glimepiride's secondary, lower-affinity site, with glimepiride's primary site being Site II. In agreement with the in vitro findings, glimepiride displaced pantoprazole from BSA more effectively when Site I was preoccupied by a Site I marker, confirming the Site I-specific nature of the interaction. Likewise, ligand-induced fluctuation was relatively lower for the glimepiride-BSA complex, suggesting its higher stability. Although their root mean squared deviation (RMSD) of Cα atoms remained the same, variation was observed at individual time points. Moreover, PCA with the force field energy data showed a clear difference between the two docked complexes. Glimepiride and pantoprazole compete for the same BSA binding pocket. The present study employed BSA as a model carrier protein for preliminary investigation of drug-protein interactions because of its established use in binding studies and its structural resemblance to human serum albumin (HSA). However, BSA cannot fully reproduce the complexity of human physiological protein-binding behavior. Therefore, the findings should be interpreted cautiously as indicative mechanistic observations rather than direct confirmation of in vivo pharmacokinetic outcomes. The present findings suggest the possibility of protein-binding interaction between glimepiride and pantoprazole, which may influence drug disposition. Further investigations using HSA-based systems and in vivo pharmacokinetic studies are necessary to establish translational relevance.

PMID 43036520
阅读全文 →
PubMedInternational urology and nephrology2026-11-15

Comparative analysis of kidney adverse events associated with four commonly used proton pump inhibitors based on the PersADE database.

Guo Xianyang X, Chen Peizhen P, Chen Rujie R, Jin Shengwei S

Proton pump inhibitors (PPIs) are widely prescribed, yet their association with kidney injury has drawn increasing concern. Using the PersADE database, we compared kidney adverse drug event (ADE) signals for four oral PPIs (omeprazole, esomeprazole, lansoprazole, pantoprazole) and described reporting patterns by age, body weight, and sex for omeprazole and esomeprazole. In this retrospective pharmacovigilance disproportionality analysis, we retrieved spontaneous reports of nine predefined MedDRA kidney ADE categories with PPIs as the primary suspected drug. Signal detection employed reporting odds ratio (ROR) and proportional reporting ratio (PRR), with positive signals defined as case count ≥ 3, ROR ≥ 2, PRR ≥ 2, and χ2 ≥ 4. Subgroup analyses were descriptive and hypothesis-generating; no formal statistical testing or adjustment for confounders was performed. Due to high missing rates for demographic variables, subgroup analyses were limited to omeprazole and esomeprazole. All four oral PPIs generated positive kidney ADE signals across multiple categories. However, pantoprazole showed no detectable signals for Acute tubular necrosis, chronic kidney disease-mineral and bone disorder or renal cancer. Higher reporting counts were observed in patients aged ≥ 70 years and those weighing > 80 kg, whereas sex was not associated with appreciable differences in reporting counts. All four PPIs exhibit clear kidney ADE signals. The subgroup findings are descriptive and hypothesis-generating rather than established risk factors. These findings suggest that clinicians may consider caution and renal function monitoring in elderly or overweight patients, although further validation is needed.

PMID 43034236
阅读全文 →
PubMedBiology2026-11-14

Beyond Acid Suppression: Mechanistic and Translational Perspectives on the Pleiotropic Pharmacology of Pantoprazole.

Satyam Shakta Mani SM, Kumar Manasvi Udaya MU, Safaii Ebrahim E, Al-Dawoodi Shams S et al.

Pantoprazole is widely used for the management of acid-related gastrointestinal disorders through inhibition of the gastric H+/K+-ATPase. Beyond its established acid-suppressive action, experimental studies have investigated its potential effects on cellular proton homeostasis, autophagy, oxidative and inflammatory signaling, cancer biology, antimicrobial resistance, glucose regulation, neurological responses, hepatic fibrosis, and iron-related outcomes. This narrative review critically examines these proposed biological effects and distinguishes established pharmacology from experimental mechanisms, preclinical findings, and human clinical evidence. Particular attention is given to the relationship between experimental concentrations and human exposure, the acid-dependent activation of pantoprazole, the distinction between direct molecular targets and downstream cellular responses, and the challenges of translating laboratory findings into clinical benefit. Pantoprazole also has a comparatively favorable CYP2C19-mediated drug-interaction profile relative to omeprazole and esomeprazole, although this advantage does not imply the absence of all clinically relevant interactions. The evidence across proposed repurposing indications remains heterogeneous, and biological activity in experimental models should not be interpreted as established therapeutic efficacy. Further exposure-informed mechanistic studies, pharmacokinetic and pharmacodynamic validation, and appropriately designed clinical trials are required to determine which proposed effects warrant clinical development. Pantoprazole should therefore be regarded as a candidate for mechanism-informed drug-repurposing research rather than an established treatment for the non-gastrointestinal indications discussed in this review.

PMID 43026948
阅读全文 →
PubMedTissue & cell2026-11-14

Gastroprotective effects of a polyphenol-enriched fraction from pulicaria undulata against indomethacin-induced gastric ulcer in rats.

Mancy Etmad M A EMA, Abdelmageed Noha N, Mahdy Mohamed A A MAA, Morad Samy A F SAF

Nonsteroidal anti-inflammatory drug (NSAID)-induced gastric injury remains a major clinical concern because acid-suppressive therapies provide incomplete protection. Plant-derived polyphenols may offer gastroprotection through antioxidant, anti-inflammatory, and mucus-preserving mechanisms. This study investigated the gastroprotective effects of a polyphenol-enriched fraction (PPEF) extracted from Pulicaria undulata against indomethacin (IND)-induced gastric ulcers in rats. Thirty-six adult male Wistar rats were equally divided into six groups: control (received saline only), IND-treated group (received IND 50 mg/Kg), IND plus pantoprazole (40 mg/Kg), and three PPEF-pretreated groups (received IND plus PPEF at 100, 300, and 500 mg/kg). Following euthanasia, stomachs were assessed for gastric weight, pH, and volume, ulcer index, oxidative stress and inflammatory markers, and histopathological changes. PPEF yielded 14.5% of the initial extract and contained high total phenolics (281.3 mg GAE/g), flavonoids (56.3 mg QE/g), and antioxidant (16.5 mg AAE/g) content. PPEF reduced ulcer severity by 72.5%. PPEF pre-treatment significantly mitigated IND-induced changes in gastric weight, pH, and volume. PPEF exhibited dose-dependent gastroprotective effects, with the 500 mg/kg dose showing the greatest efficacy. Histopathological examination showed that PPEF 500 mg/kg provided the most effective gastroprotection, preserving mucosal integrity and enhancing mucus secretion. PPEF significantly improved antioxidant markers (GSH, SOD), reduced lipid peroxidation (MDA), decreased inflammatory markers (MPO, TNF-α, IL-6) (P ≤ 0.001), and restored COX-1 and PGE2 levels, counteracting IND's effects (P ≤ 0.001). Overall, PPEF demonstrated significant gastroprotective activity against IND-induced gastric ulceration through its antioxidant, anti-inflammatory, and mucus-secretory activities, warranting further investigation as a potential therapeutic compound for the management of gastric ulceration.

PMID 43025229
阅读全文 →
PubMedNeurogastroenterology and motility2026-11-10

Targeting the Gut-Brain Axis in Functional Dyspepsia: Buspirone and Mirtazapine Improve Anxiety and PAGI-SYM Scores.

Khorashadizadeh Mahdieh M, Salmani Fatemeh F, Tavakoli Tahmine T

Functional dyspepsia is a chronic gastrointestinal disorder with uncertain causes, often linked to anxiety and depression, which can worsen symptoms and hinder treatment success. Although psychological therapies and antidepressants have shown some benefit, the role of anti-anxiety medications remains unclear. This study aims to evaluate the effectiveness of buspirone and mirtazapine in reducing symptoms and improving the quality of life for patients with functional dyspepsia. In a semi experimental study, 71 patients with functional dyspepsia were randomized to receive either buspirone 15 mg, mirtazapine 7.5 mg, or pantoprazole 40 mg once daily for 12 weeks. Outcomes-anxiety severity, dyspepsia symptom score, quality of life, and adverse events-were assessed at baseline and monthly. Efficacy was analyzed by repeated-measures ANOVA and adverse event rates by chi-square tests. Both buspirone and mirtazapine significantly outperformed pantoprazole alone in reducing anxiety (buspirone vs. control at 3 months, p = 0.01; both active treatments vs. control, p < 0.05) and in alleviating functional dyspepsia symptoms by Week 12 (both vs. control, p < 0.05), with no difference between the two active drugs. This study suggests that buspirone and mirtazapine are effective in reducing anxiety and improving symptoms in patients with functional dyspepsia. These findings highlight the potential role of anti-anxiety medications in managing both the psychological and gastrointestinal aspects of this disorder.

PMID 43004923
阅读全文 →

注册免费账户还可查看另外 2434 篇文献

免费注册查看全部文献 →

了解更多pantoprazole